Renee Lentini - 22 Dec 2023 Form 4 Insider Report for ImmunoGen, Inc.

Role
VP & PRIN ACCTG OFFICER
Signature
/s/ Renee Lentini
Issuer symbol
N/A
Transactions as of
22 Dec 2023
Net transactions value
-$194,738
Form type
4
Filing time
27 Dec 2023, 19:08:05 UTC
Previous filing
08 Nov 2023
Next filing
03 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGN Common Stock Options Exercise $0 +15,000 $0.000000 15,000 22 Dec 2023 Direct
transaction IMGN Common Stock Sale $194,738 -6,548 -44% $29.74 8,452 26 Dec 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Restricted Stock Unit Options Exercise $0 -15,000 -40% $0.000000 22,500 22 Dec 2023 Common Stock 15,000 $0.000000 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Effected pursuant to a trading plan adopted on June 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.74 to $29.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
F3 Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F4 37,500 RSUs were granted on December 22, 2022, with 40% of such RSUs vesting on the one-year anniversary of the date of grant and the remaining 60% of such RSUs vesting on the eighteen-month anniversary of the date of grant, subject to continued service through each vesting date.